QIAGEN N.V. — 2012 Form 20-F Summary
Business context and reporting period. This is QIAGEN N.V.’s audited annual report for the fiscal year ended December 31, 2012, prepared under U.S. GAAP—not a standalone fourth-quarter report. QIAGEN sells sample and assay consumables and laboratory automation systems across Molecular Diagnostics, Applied Testing, Pharma and Academia. Molecular Diagnostics represented approximately 49% of sales; consumables and related revenues were 87%. Amounts below are U.S. dollars.
Key financial metrics
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Net sales | $1,254.5 million | $1,169.7 million |
| Gross profit / gross margin | $824.0 million / 66% | $749.8 million / 64% |
| Operating income / operating margin | $169.8 million / 13.5% | $99.6 million / 8.5% |
| Net income attributable to QIAGEN N.V. | $129.5 million; diluted EPS $0.54 | $96.0 million; diluted EPS $0.40 |
| Cash from operating activities | $244.9 million | $244.8 million |
| Capital expenditures | $102.0 million | $86.8 million |
| Cash and cash equivalents at year-end | $394.0 million | $221.1 million |
| Short-term investments / working capital at year-end | $90.5 million / $725.8 million | $54.6 million / $293.8 million |
| Long-term debt, net of current portion | $846.0 million | $446.0 million |
Operating cash flow less capital expenditures was approximately $142.9 million. Investing activities used $300.9 million, including $132.0 million for acquisitions; financing activities provided $226.6 million. QIAGEN reported $847.0 million of total long-term debt, of which $0.9 million was current. It also had $577.9 million of available credit facilities, undrawn at year-end. Contractual cash obligations, including interest, totaled $1.326 billion.
Material changes versus the prior year
- Sales rose 7% as reported. Management attributed six percentage points of growth to acquisitions, four to the rest of the portfolio, and a three-percentage-point offset to currency movements.
- Gross margin improved to 66% from 64%. Operating income rose 71%, partly reflecting lower restructuring and impairment charges than in 2011.
- Net income attributable to QIAGEN increased to $129.5 million from $96.0 million. The effective tax rate rose to 11% from 1%; 2011’s unusually low rate reflected restructuring effects and tax planning.
- Sales growth varied by customer class: Molecular Diagnostics +13%, Applied Testing +19%, Pharma +3%, and Academia −2%. Regional growth was strongest in Asia-Pacific/Japan (+14%); Americas grew 8% and Europe/Middle East/Africa 2%.
- Cash increased by $172.9 million year over year. QIAGEN issued $400 million of senior notes, used part of the proceeds to repay short-term borrowing, and repurchased 1.9 million shares for $35.7 million.
Outlook, management commentary, risks and unusual items
- Management said existing cash, operating funds and available financing were expected to fund planned operations and expansion during the coming year. It anticipated beginning placements of its next-generation sequencing workflow with selected customer groups in 2013; no consolidated numerical earnings or sales guidance is stated in the provided filing text.
- Management expected additional restructuring charges in 2013 and continued increases in acquisition-related intangible amortization. The U.S. medical-device excise tax was expected to cost up to $6.0 million annually beginning in 2013.
- Restructuring charges were $41.0 million in 2012 versus $74.9 million in 2011. They included workforce, facility, contract and project-abandonment costs. The company also recorded $2.0 million of intangible-asset impairment and $3.4 million of impairment on a cost-method investment in 2012.
- Other expense increased to $24.7 million from $3.4 million, primarily due to foreign-currency losses and lower interest income. Foreign-currency transaction losses were $7.2 million in 2012, compared with a $12.4 million gain in 2011.
- Key risks include reimbursement and healthcare cost pressure, dependence on HPV products and a limited number of U.S. reference-laboratory customers, uncertain research funding, competition, regulatory approval and adoption risks, acquisition integration, foreign exchange, and supplier or production interruptions. U.S. HPV product sales represented approximately 13% of total sales.
- Goodwill was $1.760 billion and net intangible assets were $853.9 million at year-end. Management reported no goodwill impairment in its annual test and stated that a 10% reduction in projected cash flows would not have changed the reported goodwill value.
- Potential contingent acquisition payments totaled up to $134.2 million, subject to milestones; $19.0 million was accrued at year-end. Uncertain tax-position liabilities, including interest and penalties, were estimated at $13.8 million. Management said pending litigation was not expected to have a material adverse effect, while noting litigation outcomes are uncertain.
Important facts for investors to verify
- Reconcile the reported 7% sales growth with management’s stated acquisition, portfolio and currency contributions; assess the persistence of organic growth by customer class and region.
- Determine how much of the improvement in operating income reflects recurring operating performance versus lower restructuring and impairment charges, and monitor expected 2013 restructuring costs.
- Review debt maturities, interest and covenant terms, including the $400 million senior notes and convertible-note repayment or conversion provisions, alongside the company’s cash and undrawn facilities.
- Assess the assumptions supporting the substantial goodwill and intangible-asset balances and the contingent consideration owed on acquisitions.
- Track 2013 execution risks and costs: NGS placements, QIAsymphony adoption, regulatory approvals, academic research funding, reimbursement, HPV demand and the medical-device excise tax.
- The filing provides annual results and annual comparisons; it does not provide a clear standalone fourth-quarter financial summary in the supplied text.